Onconova Therapeutics, Inc. announced today the publication of positive results from a first-in-human Phase I clinical trial of its lead anticancer drug, ON 01910.Na, in advanced refractory solid tumors. The publication will be online today in the Journal of Clinical Oncology and will appear in a future print edition of the journal. A first-in-class targeted therapy, ON 01910.
Continued here:
Onconova Announces Publication Of Positive Phase I Results For Lead Anticancer Compound In Journal Of Clinical Oncology
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.